Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex, Heritage, Breckenridge US Price-Fixing Settlements Could Top $50m

Trio Of Manufacturers Look To Put Pen To Paper In Latest Antitrust MDL Settlements

Executive Summary

Direct purchasers of drugs from a trio of generics manufacturers in the US say they will receive payments that are fair and reasonable, under settled agreements that have been put before a judge in Pennsylvania.

You may also be interested in...



Teva Pays Out $225m To Settle Criminal Price-Fixing Charges In US

Teva has agreed to pay a $225m fine, as well as donating $50m worth of medicines and divesting a product from its portfolio, as part of a settlement with the US Department of Justice over criminal price-fixing charges. Meanwhile, Glenmark has also struck a $30m settlement with the DoJ.

Sandoz, Apotex And Taro Strike Civil Settlements On Price-Fixing

Three civil settlements worth more than $447m in total have been reached with the US Department of Justice by Sandoz, Apotex and Sun’s Taro to resolve allegations over price-fixing. The deals follow criminal penalties previously paid by the three companies.

Heritage Clarifies No Guilty Plea In US Settlement

Heritage has clarified that its recent settlement deal with the US Department of Justice over price-fixing allegations did not include the company entering a guilty plea.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel